Appleby P, Telford G, Naylor G B
Boots Pharmaceuticals Research Department, Boots Company PLC, Nottingham, UK.
Clin Exp Immunol. 1993 Sep;93(3):313-7. doi: 10.1111/j.1365-2249.1993.tb08178.x.
Autoimmune disease in NZB/W F1 mice was treated from 23 weeks of age with the novel immunomodulator BTS 63155 and, for comparative purposes, the established immunosuppressive agent cyclosporin A. Both drugs significantly improved survival compared with untreated controls. Lupus nephritis was also significantly reduced in the drug-treated groups, and this was related to reduced glomerular deposition of IgG. Autoantibody (ANA) levels were lowered by treatment with cyclosporin A, but not by BTS 63155. This latter finding may indicate a different mode of action for the two drugs. In a long term study, neither drug effected a complete cure, as autoimmune disease recurred on withdrawal of drug treatment.
从23周龄起，用新型免疫调节剂BTS 63155对NZB/W F1小鼠的自身免疫性疾病进行治疗，为作比较，还用了已有的免疫抑制剂环孢素A。与未治疗的对照组相比，两种药物均显著提高了存活率。药物治疗组的狼疮性肾炎也显著减轻，这与IgG在肾小球的沉积减少有关。用环孢素A治疗可降低自身抗体（ANA）水平，但BTS 63155则无此作用。后一发现可能表明两种药物的作用方式不同。在一项长期研究中，两种药物均未实现完全治愈，因为停药后自身免疫性疾病会复发。
